Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer
Status:
Completed
Trial end date:
2020-10-15
Target enrollment:
Participant gender:
Summary
Randomized, double-blind, placebo controlled, dose finding Phase 2 study comparing oral daily
dosing of VERU-944 after a week of loading (daily dosing) with placebo to ameliorate the
vasomotor symptoms resulting from androgen deprivation therapy in men with advanced prostate
cancer